ESCMID works throughout the year to propose and endorse quality guidelines to members and the global professional community. Below is a list of guidance documents that are currently under development. Explore the details of each guidance document and follow the evolution of their progress via the links provided.
The status of each project is defined based on the steps of the GIN-McMaster Guideline Development Checklist.
|
Title |
Chair |
Approval Date |
Status |
Details |
|---|---|---|---|---|
|
ESCMID guideline on clinician-targeted interventions to optimise treatment for common acute infections in primary care |
Oliver Van Hecke, Belgium |
February 2026 |
PICO - Question Generation (ongoing) |
|
|
Guidelines for management of infectious complications after chimeric antigen receptor T cell therapy and bispecific antibodies for haematological malignancies |
Maddalena Giannella, Italy |
February 2026 |
PICO - Question Generation (ongoing) |
|
|
ESCMID Guidelines for the diagnosis, clinical management and follow-up of patients with alveolar echinococcosis |
Beate Gruener, Germany |
February 2026 |
PICO - Question Generation (ongoing) |
|
|
Group A streptococcal infections |
Katherine Gibney, Australia |
February 2026 |
PICO - Question Generation (ongoing) |
|
|
Pneumocystis pneumonia |
Alexandre Alanio, France |
February 2026 |
PICO - Question Generation (ongoing) |
|
|
ESCMID rapid guidelines on Mpox |
Pikka Jokelainen, Denmark |
February 2025 |
Screening of literature (ongoing) |
|
|
Infection control strategies and interventions to prevent ventilator-associated pneumonia in adult patients |
Gabriel Birgand, France and Henri van Werkhoven, Netherlands |
February 2025 |
Screening of literature (ongoing) / Data extraction (ongoing) |
|
|
Selection and duration of antibiotic treatment in infectious aortitis and vascular graft and endograft infections |
Marjan Wouthuyzen-Bakker, Netherlands |
February 2025 |
Screening of literature (ongoing) / Data extraction (ongoing) |
|
|
Nomenclature, diagnosis and treatment of acute and chronic Q fever |
Chantal Rovers, Netherlands |
February 2025 |
Data extraction (ongoing) |
|
|
The update of the 2021 ESCMID guidelines for the treatment of infections caused by multidrug-resistant Gram-negative bacilli |
Mical Paul, Israel |
February 2025 |
Data extraction (ongoing) |
|
|
Vaccination of the immunocompromised host |
Olivier Epaulard, France |
March 2023 |
Writing the manuscriot (ongoing) |
|
|
Dosing of antimicrobials in patients with renal impairment with or without RRT |
Thomas Tängdén, Sweden |
March 2023 |
Judging Quality, Strength or Certainty of a Body of Evidence - GRADE (ongoing) |
|
|
Update of the 2014 ESCMID guidelines for the management of the infection prevention & control measures to reduce transmission of multidrug-resistant Gram-negative bacteria in hospitalized patients |
Evelina Tacconelli, Italy |
December 2020 |
EtDs (ongoing) |
|
|
Diagnosis and management of infective encephalitis (ESCMID/EAN) |
Thomas Whitfield, United States (ESCMID representative) |
April 2018 |
Reporting (Ongoing) (September 2025) |
|
|
Management of Staphylococcus aureus bacteremia (IDSA/ESCMID) |
Winfried Kern, Germany and François Vandenesch, France |
January 2017 |
Developing Recommendations and Determining their Strength (EtDs) (March 2024) |
|
There are currently no documents under public consultation.
Please check back in at a later date if you wish to participate in the future.
Registration for ESCMID Global 2026 in Munich is now open.
Register now to get the standard registration fee and attend the world’s most eminent event in the field of infection.